@article {2068, title = {Cross-Platform Identification and Validation of Uveal Melanoma Vitreous Protein Biomarkers.}, journal = {Invest Ophthalmol Vis Sci}, volume = {64}, year = {2023}, month = {2023 Nov 01}, pages = {14}, abstract = {

PURPOSE: The purpose of this study was to profile protein expression liquid vitreous biopsies from patients with uveal melanoma (UM) using mass spectrometry to identify prognostic biomarkers, signaling pathways, and therapeutic targets.

METHODS: Vitreous biopsies were collected from two cohorts in a pilot study: comparative control eyes with epiretinal membranes (ERM; n = 3) and test eyes with UM (n = 8). Samples were analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Identified proteins were compared to data from a targeted multiplex ELISA proteomics platform.

RESULTS: A total of 69 significantly elevated proteins were detected in the UM vitreous, including LYVE-1. LC-MS/MS identified 62 significantly upregulated proteins in UM vitreous that were not previously identified by ELISA. Analysis of differential protein expression by tumor molecular classification (gene expression profiling [GEP] and preferentially expressed antigen in melanoma [PRAME]) further identified proteins that correlated with these classifications. Patients with high-risk GEP tumors displayed elevated vitreous expression of HGFR (fold-change [FC] = 2.66E\ +\ 03, P value = 0.003) and PYGL (FC = 1.02E\ +\ 04, P = 1.72E-08). Patients with PRAME positive tumors displayed elevated vitreous expression of ENPP-2 (FC = 3.21, P = 0.04), NEO1 (FC = 2.65E\ +\ 03, P = 0.002), and LRP1 (FC = 5.59E\ +\ 02, P value = 0.01). IGF regulatory effectors were highly represented (P value = 1.74E-16). Cross-platform analysis validated seven proteins identified by ELISA and LC-MS/MS.

CONCLUSIONS: Proteomic analysis of liquid biopsies may provide prognostic information supporting gene expression of tumor biopsies. The use of multiple protein detection platforms in the same patient samples increases the sensitivity of candidate biomarker detection and allows for precise characterization of the vitreous proteome.

}, keywords = {Antigens, Neoplasm, Biomarkers, Chromatography, Liquid, Humans, Melanoma, Pilot Projects, Proteomics, Tandem Mass Spectrometry, Uveal Neoplasms}, issn = {1552-5783}, doi = {10.1167/iovs.64.14.14}, author = {Velez, Gabriel and Wolf, Julian and Dufour, Antoine and Mruthyunjaya, Prithvi and Mahajan, Vinit B} } @article {1091, title = {Optical Coherence Tomography Angiography of RPGR-Associated Retinitis Pigmentosa Suggests Foveal Avascular Zone is a Biomarker for Vision Loss.}, journal = {Ophthalmic Surg Lasers Imaging Retina}, volume = {50}, year = {2019}, month = {2019 02 01}, pages = {e44-e48}, abstract = {

RPGR-associated retinitis pigmentosa (RP) is a progressive disease with retina degeneration. Optical coherence tomography angiography (OCTA) is an imaging technique that provides novel insights. The authors report two affected male siblings who underwent OCTA imaging. The area of the foveal avascular zone (FAZ) was measured. Although the younger sibling exhibited more advanced clinical disease, his visual acuity was superior to his older sibling. OCTA imaging revealed a better preserved FAZ in the younger sibling as the reason for this. It also highlighted attenuation of choriocapillaris / choroid layers as biomarkers for disease severity. This provides new insights into retinal degeneration in RPGR-associated RP. [Ophthalmic Surg Lasers Imaging Retina. 2019;50:e44-e48.].

}, keywords = {Biomarkers, Capillaries, Choroid, Eye Proteins, Fluorescein Angiography, Fovea Centralis, Humans, Male, Middle Aged, Retinitis Pigmentosa, Tomography, Optical Coherence, Vision Disorders}, issn = {2325-8179}, doi = {10.3928/23258160-20190129-18}, author = {Tang, Peter H and Jauregui, Ruben and Tsang, Stephen H and Bassuk, Alexander G and Mahajan, Vinit B} }